ArticleAnalytical chemistry2026
A Selective, Class-Specific Aptamer for Fentanyl Analog Screening.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fentanyl and its analogs pose considerable dangers to public health and safety, and the development of simple tests that can detect these harmful substances accurately and rapidly could control their currently unchecked spread and thereby safeguard lives. Here, we use systematic evolution of ligands by exponential enrichment (SELEX) to isolate an aptamer that displays a rare blend of high affinity and broad cross-reactivity to 139 fentanyl analogs, alongside excellent specificity against nontarget interferents, including cutting agents, adulterants, and other drugs of abuse. We demonstrate the utility of this aptamer by developing a single-step colorimetric dye-displacement assay that can detect diverse fentanyl analogs within seconds with a simple mix-and-read format. The analog coverage of our assay rivals that of commercial immunoassay-based fentanyl tests while offering better specificity against substances that commonly trigger false positives in those tests, such as diphenhydramine, lidocaine, and methamphetamine. Our findings indicate that aptamers may be fundamentally better suited for achieving broad but specific detection of structurally related classes of molecules relative to other commonly used receptors, such as antibodies, due to their excellent and controllable binding properties, among other benefits, including low cost and high stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.